Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12357051 | 1.00 | KDM4E (0.65) | KDM4ESMN1; SMN2TSHRSLC6A2SLC6A4 | |
| SCHEMBL12737720 | 0.83 | — | — | |
| SCHEMBL19672356 | 0.83 | — | — | |
| SCHEMBL13997259 | 0.83 | KDM4E (0.58) | KDM4ESMN1; SMN2TSHRSLC6A2ALDH1A1 | |
| Meglumine SCHEMBL4274398 | 0.80 | KDM4E (0.91) | KDM4ESMN1; SMN2TSHRSLC6A2SLC6A4 | |
| SCHEMBL414431 | 0.80 | TSHR (0.47) | KDM4ETSHRALDH1A1TDP1LMNA | |
| SCHEMBL12409518 | 0.80 | TSHR (0.47) | KDM4ETSHRALDH1A1TDP1LMNA | |
| SCHEMBL15496474 | 0.80 | TSHR (0.47) | KDM4ETSHRALDH1A1TDP1LMNA | |
| Meglumine SCHEMBL23106596 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2TSHRSLC6A2SLC6A4 | |
| Meglumine SCHEMBL22562873 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2TSHRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-9783503-B2 | Crystalline forms of an estrogen receptor modulator | GENENTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9758484-B2 | Base addition salts of nitroxoline and uses thereof | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) | 2017-09-12 | — | — | US | disclosed |
| US-9586885-B2 | Compounds for use in the treatment of inflammatory bowel disease | VENANTIUS LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20160039770-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR | GENENTECH, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160031819-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | PAN-SCIENTIFIC HOLDINGS CO., LTD. (VG) | 2016-02-04 | — | — | US | disclosed |
| US-8735602-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2014-05-27 | — | — | US | disclosed |
| US-20140107194-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF IMMUNE RELATED INFLAMMATORY DISEASE | VENANTIUS LIMITED (IE) | 2014-04-17 | — | — | US | disclosed |
| US-20130072692-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PREOCESSES FOR THEIR MANUFACTURE. | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20130017156-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | BILGIC MAHMUT (TR) | 2013-01-17 | — | — | US | disclosed |
| US-8138221-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOIGES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| US-7674792-B2 | 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072692-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PREOCESSES FOR THEIR MANUFACTURE. | TPH1, TMSB10, TRPC1 | KDM4E 2875/4885SMN1; SMN2 4008/4885TSHR 3344/4885 |
| US-20140107194-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF IMMUNE RELATED INFLAMMATORY DISEASE | AADAT, ASNS, BCAT2 | KDM4E 2185/4885SMN1; SMN2 4025/4885TSHR 731/4885 |
| US-20130017156-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | C1R, CFD, CSF3R | KDM4E 2705/4885SMN1; SMN2 3862/4885TSHR 3260/4885 |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | HYPK, HIPK3, HIPK1 | KDM4E 1579/4885SMN1; SMN2 4529/4885TSHR 4322/4885 |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | TPH1, CACNA1G, CACNA1S | KDM4E 2406/4885SMN1; SMN2 3873/4885TSHR 2764/4885 |
| US-20160039770-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | KDM4E 962/4885SMN1; SMN2 3979/4885TSHR 187/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | KDM4E 1333/4885SMN1; SMN2 3394/4885TSHR 3129/4885 |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | HCLS1, HIPK3, HYPK | KDM4E 1151/4885SMN1; SMN2 2530/4885TSHR 4810/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | KDM4E 2784/4885SMN1; SMN2 113/4885TSHR 77/4885 |
| US-20160031819-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | SLC28A1, SLC28A2, NNT | KDM4E 4309/4885SMN1; SMN2 1366/4885TSHR 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.